Re­gen­eron and Sanofi land the big one, win­ning FDA ap­proval for their megablock­buster hope­ful Dupix­ent

The FDA has ap­proved the new eczema drug dupilum­ab from Re­gen­eron and Sanofi, of­fi­cial­ly launch­ing a new drug that is like­ly on course to cre­at­ing a megablock­buster fran­chise for these two part­ners. Wide­ly tapped as the biggest pro­gram in the in­dus­try’s pipeline this year, dupilum­ab now will be brand­ed as Dupix­ent. And the mar­ket here could be worth up­wards of $5 bil­lion a year.

“Peo­ple with mod­er­ate-to se­vere atopic der­mati­tis cope with in­tense, some­times un­bear­able symp­toms that can im­pact them for most of their lives,” said Julie Block, the CEO of the Na­tion­al Eczema As­so­ci­a­tion. “To date, there have been few op­tions avail­able to treat peo­ple with mod­er­ate-to-se­vere atopic der­mati­tis who have un­con­trolled dis­ease. That’s why to­day’s ap­proval of Dupix­ent is so im­por­tant for our com­mu­ni­ty. Now we have a treat­ment that is ex­pect­ed to help ad­dress pa­tients suf­fer­ing from this dev­as­tat­ing dis­ease.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER